About Us

Company Info

AskGene Pharma, Inc. (“AskGene”) is a U.S. based biotechnology firm located in Camarillo, California. AskGene’s mission is to develop and bring our patients “me-too” and biosuperior molecules with validated targets. Currently, we have monoclonal antibodies, bi-specific antibodies and fusion proteins in our development pipeline.

AskGene was founded by a team of highly accomplished scientists from leading biotech organizations and financially supported by Jiangsu Aosaikang pharmaceuticals (China A share market 002755). Since then, AskGene has leveraged its scientific strengths and technical infrastructure to rapidly develop therapeutic molecules (monoclonal antibodies and fusion proteins), with its first IND approved within 7 months from its submission to CFDA and entering phase 1 clinical trial in 2017. Currently, AskGene has multiple ongoing clinical trials in USA and China.

AskGene is equipped with most advanced R&D facilities with above 10000 sq.ft R&D space in southern California and a manufacturing pilot plant in Nanjing ready to launch in 2019 Q3. Development is carried out with high standards of safety, efficacy and efficiency. We require our employees to have professional skills and in-depth knowledge about commercialization of recombinant therapeutics.

About the Management Team

Jian-Feng (Jeff) Lu, Ph.D. – President and CEO

Jeff Lu, Ph.D., has been President and Chief Executive Officer of AskGene Pharma since its inception. Dr. Lu has more than 25 years of experience in clinical pharmacology including more than 12 years of experience in PK/PD and drug development across various therapeutic areas at Genentech and Amgen. Dr. Lu’s previous posts included Consulting Director at Quantitative Solution and increasing responsibility up to Scientific Director at Amgen. During his tenure, he participated in the first BLA filing of Avastin and the first NDA filing of Tarceva. Additionally, Dr. Lu was responsible for PK/PD assessment, dose selection, and study design for many projects ranging from pre-clinical stage through phase III, which included biologics, small molecule and antibody-drug conjugate programs. Dr. Lu received his Ph.D. in Pharmaceutics from China Pharmaceutical University and completed his post-doctoral training at the University of California San Francisco (UCSF). Dr. Lu is a guest professor at Jiangnan University. Dr. Lu was also invited to draft the biosimilar guidance for CFDA.

Yuefeng Lu, Ph.D., – Vice President of Process Development and Chief Scientific Officer

Dr. Yuefeng Lu joined AskGene in June 2013. From 2002 to 2013, Dr. Lu was Principal Scientist of Process Development at Amgen, where he led process development, pivotal and commercial tech transfer and/or manufacturing support for several recombinant antibody and fusion protein projects. Dr. Lu has over 16 years of biotech industrial experience. He had previously worked at Protein Design Labs, GeneTrol, and Pan Pacific Pharmaceuticals. Dr. Lu received his Ph.D. degree in Biochemistry from University of Minnesota, Twin Cities, and completed his post-doctoral training at Stanford University. Dr. Lu is the co-inventor of six issued and pending patents.

Ming Li, Ph.D. – Director of Analytical Development

Dr. Li joined AskGene in September of 2016.  Dr. Li has over 16 years of experience in recombinant and plasma therapeutic protein development and manufacturing at various biotech companies.  Prior to joining AskGene, she was senior manager of Analytical Development at Shire, where she was responsible for assay development to support product and process development.  She was also responsible for manufacturing investigations and provided quality control support.  Dr. Li has previously worked at Baxter and Amgen on therapeutic protein drug development and GMP manufacturing for cancer, osteoporosis, and hemophilia disease indications.  Dr. Li received her doctorate degree in Biochemistry and Biophysics from the University of Minnesota, and completed her post-doctoral training at California Institute of Technology (Caltech).  Dr. Li is the author of about twenty publications in peer-reviewed journals, and has been a speaker on biotech analytical development at various national conferences.

Ray Chuang, Ph.D. – Senior Director Cell Line Development

Dr. Chuang joined AskGene in September of 2018.  Prior to joining our company, he was R&D Manager of Cell Biology at Thermo Fisher Scientific’s TDX division. He also worked at Shire Pharmaceuticals (acquired by Takeda in 2019) and Genesun Biopharmaceuticals as Associate Director of Cell Line Development, and prior to that was an R&D Scientist at Multispan.  Dr. Chuang completed his postdoctoral fellowship at Johnson & Johnson Pharmaceuticals. He has over 16 years of industrial experience in research discovery and cell line development in both the diagnostic and pharmaceutical industries. Dr. Chuang received his PhD in Cell & Development Biology from the University of Michigan, at Ann Arbor and postdoctoral training at Salk Institute for Biological Studies.

Chen Yao, Ph.D.  – Director of Upstream Process Development

Dr. Yao joined AskGene in September of 2012. During his service in AskGene, he is taking various roles with increasing responsibilities. He has successfully designed and led the upstream process tech transfer/scale-up of one of the AskGene key project. Dr.Yao has authored 10 scientific paper and 1 patent. Dr. Yao received his Ph.D in pathology from Case Western Reserve University and BS in pharmaceutical science from China Pharmaceutical University.